Related Experiment Video
Updated: Jul 26, 2025
10:24
Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
Published on: February 12, 2018
10.2K
ASSOCIATION OF ORAL MONTELUKAST WITH REDUCED ODDS OF DEVELOPING EXUDATIVE AGE-RELATED MACULAR DEGENERATION
Wataru Matsumiya1,2, Irmak Karaca1, Brandon Huy Pham1
1Spencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, California.
Retina (Philadelphia, Pa.)
|June 20, 2023
Summary
Oral montelukast, a cysteinyl leukotriene receptor 1 antagonist, was associated with lower odds of developing exudative age-related macular degeneration (exAMD). This finding suggests a potential protective effect of montelukast against exAMD progression.
Area of Science:
- Ophthalmology
- Pharmacology
- Epidemiology
Background:
- Exudative age-related macular degeneration (exAMD) is a leading cause of vision loss.
- Understanding risk factors and protective agents for exAMD is crucial for patient care.
Purpose of the Study:
- To investigate the association between oral montelukast use and the development of exAMD.
- To evaluate if montelukast's selective antagonism of cysteinyl leukotriene receptor 1 influences exAMD risk.
Main Methods:
- A case-control study involving 1913 exAMD patients and 1913 matched controls.
- Subanalysis included 324 patients with nonexudative AMD to assess progression to exAMD.
Main Results:
- Montelukast use was linked to significantly reduced odds of exAMD (adjusted OR: 0.50).
- Montelukast also showed reduced odds of progression from nonexudative to exudative AMD (adjusted OR: 0.53).
- Caucasian race, smoking, and nonexudative AMD increased exAMD odds, while atopic disease showed a protective association.
Conclusions:
- Oral montelukast use is associated with decreased odds of developing exAMD.
- Montelukast may play a protective role in the pathogenesis of age-related macular degeneration.
More Related Videos
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
372
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
372
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
357
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
357
01:27Open Angle Glaucoma: Treatment
491
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
491
01:24Antiasthma Drugs: Methylxanthines
280
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
280
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
315
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
315
01:28Angle Closure Glaucoma: Treatment
578
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
578